logo
Share SHARE
FONT-SIZE Plus   Neg

Northeast Utilities Q4 Profit Rises - Quick Facts

Northeast Utilities (NU) Tuesday said its profit for the fourth quarter increased, helped mainly by higher revenues.

Net income for the quarter rose to $176.5 million from $114.7 million in the comparable quarter last year. On a per share basis, profit fell to $0.55 from $0.64, echoing a lower number of outstanding common stock.

On average, 10 analysts polled by Thomson Reuters expected the company to earn $0.58 per share for the quarter. Analysts' estimates typically exclude special items.

Meanwhile, operating revenues totaled $1.68 billion, up from $1.06 billion a year ago, while five analysts expected revenues of $1.87 billion.

Going ahead to the fiscal 2013, the company Also today, reaffirmed its 2013 earnings guidance between $2.40 per share and $2.60 per share, as well as its longer term earnings per share growth rate of 6 percent to 9 percent. Analysts expect the company to earn $2.54 for the quarter. The company added that the fourth quarter results included approximately $2.1 million or $0.01 per share of after-tax charges.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year. Eli Lilly and Co. (LLY) reported a loss for the first quarter of 2017 compared to profit in the prior year, primarily hurt by lower operating income, partially offset by higher other income. But, quarterly revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products. Capricor Therapeutics, Inc., a clinical-stage biotechnology company for cardiac and other medical conditions, announced Tuesday positive six-month results from the randomized phase I/II HOPE clinical trial in Duchenne muscular dystrophy or DMD. The HOPE clinical trial was designed to evaluate the safety and exploratory efficacy of CAP-1002.
comments powered by Disqus
Follow RTT